<DOC>
<DOCNO>EP-0657170</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Products for the application of high initial doses of cetrorelix and preparation of a combined package for use in treating diseases
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3504	A61K3809	A61J100	A61K900	A61K900	A61K914	A61K3800	A61K3502	A61K914	A61K3808	A61K922	A61K922	A61J103	A61K3800	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61J	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61J	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K35	A61K38	A61J1	A61K9	A61K9	A61K9	A61K38	A61K35	A61K9	A61K38	A61K9	A61K9	A61J1	A61K38	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The product according to the invention is used for the therapy of benign and malignant oncoses and contains the initial dose of cetrorelix acetate and one or more maintenance doses of cetrorelix acetate, cetrorelix embonate or a slow release form of cetrorelix, in the form of a combination product for sequential therapeutic use.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
ASTA MEDICA AG
</APPLICANT-NAME>
<APPLICANT-NAME>
ASTA MEDICA AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
ENGEL JUERGEN PROF
</INVENTOR-NAME>
<INVENTOR-NAME>
HILGARD PETER DR
</INVENTOR-NAME>
<INVENTOR-NAME>
REISSMANN THOMAS DR
</INVENTOR-NAME>
<INVENTOR-NAME>
ENGEL, JUERGEN, PROF.
</INVENTOR-NAME>
<INVENTOR-NAME>
HILGARD, PETER, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
REISSMANN, THOMAS, DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Pharmaceutical pack, characterized in that it
contains, in one container, the initial dose and, in

one or more other containers, the maintenance dose of
an LH-RH antagonist, where the initial dose is between

1 and 60 mg per day and is higher than the maintenance
dose, which is between 0.1 and 10 mg per day and is not

sufficiently active by itself.
Pharmaceutical pack according to Claim 1,
characterized in that the LH-RH antagonist is a

lyophilizate of cetrorelix.
Pharmaceutical pack according to Claim 2,
characterized in that the LH-RH antagonist, which is

used as a maintenance dose, is a delayed-release form
of cetrorelix.
Pharmaceutical pack according to Claim 3,
characterized in that the LH-RH antagonist, which is

used as maintenance dose, is present as cetrorelix
embonate.
Process for the production of a pharmaceutical
pack according to Claim 2, characterized in that the

solution of cetrorelix lyophilizate is dispensed into
the containers and then lyophilized, and the containers

are sealed.
Pharmaceutical pack according to Claim 1 for
use in the therapy of prostate cancer.
Pharmaceutical pack according to Claim 1 for
use in the therapy of endometriosis.
Pharmaceutical pack according to Claim 1 for
use in the therapy of benign prostrate hypertrophy.
Pharmaceutical pack according to Claim 1 for
use in the therapy of mastocarcinoma.
Pharmaceutical pack according to Claim 1 for
use in the therapy of ovarian carcinoma.
Pharmaceutical pack according to Claim 1 for
use in the therapy of uterine fibroma.
Pharmaceutical pack according to Claim 1 for
use in the therapy of pubertas praecox. 
Pack for use in male prophylaxis, characterized
in that it contains, in one container, the initial

dose, and in one or more other containers, the
maintenance dose of an LH-RH antagonist, where the

initial dose is between 1 and 60 mg per day and is
higher than the maintenance dose, which is between 0.1

and 10 mg per day and is not sufficiently active by
itself.
</CLAIMS>
</TEXT>
</DOC>
